Research Article| Volume 306, ISSUE 1-2, P167-169, July 15, 2011

Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy

Published:August 18, 2010DOI:


      Many new therapies have become available for multiple sclerosis patients during the last decade. They are mainly effective in the early relapsing stage of the disease. Despite this undisputed progress, there are still major deficits in the treatment of the patients. Effective anti-inflammatory treatments profoundly decrease disease activity, although this may occur on the expense of a partially impaired immune surveillance of the central nervous system. Furthermore, the clinical outcome of recent trials does not always meet the expectations of the neuroimmunological community. This suggests that preclinical testing in experimental models, although useful and necessary, has its limitations. For treatment of the progressive stage of the disease blood brain barrier penetration of drugs appears to be one crucial issue. Additionally, little is known on the immunological mechanisms of slow burning inflammation present in the brain of patients with progressive MS. Finally, it is suggested that neuroprotective strategies, which target mitochondrial injury and its downstream effects on neurons and axons are promising future therapeutic options.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lassmann H.
        • Brück W.
        • Lucchinetti C.
        The immunopathology of multiple sclerosis: an overview.
        Brain Pathol. 2007; 17: 210-218
        • Lublin F.D.
        • Reingold S.C.
        Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
        Neurology. 1996; 46: 907-911
        • Hohlfeld R.
        • Wekerle H.
        Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.
        Proc Natl Acad Sci USA. 2004; 101: 14599-14606
        • Wiendl H.
        • Hohlfeld R.
        Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
        Neurology. 2009; 72: 1008-1015
        • Giacomini P.S.
        • Darlington P.J.
        • Bar-Or A.
        Emerging multiple sclerosis disease-modifying therapies.
        Curr Opin Neurol. 2009; 22: 226-232
        • Segal B.M.
        • Constantinescu C.S.
        • Raychaudhuri A.
        • Kim L.
        • Fidelus-Gort R.
        • Ustekinumab MS Investigators
        Repeated subcutaneous injections of Il12/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
        Lancet Neurol. 2008; 7: 796-804
        • Hauser S.L.
        • Waubant E.
        • Arnold D.L.
        • Vollmer T.
        • Antel J.
        • Fox R.J.
        • et al.
        HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
        N Engl J Med. 2008; 358: 676-688
        • Lassmann H.
        Comparative Neuropatholohy of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Heidelberg, Springer Vlg, Berlin1983: 1-135
        • Taoufik E.
        • Tseveleki V.
        • Euagelidou M.
        • Emmanouil M.
        • Voulgari-Kokota A.
        • Haralambous S.
        • et al.
        Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
        Neurodegener Dis. 2008; 5: 32-37
        • Babbe H.
        • Roers A.
        • Waisman A.
        • Lassmann H.
        • Goebels N.
        • Hohlfeld R.
        • et al.
        Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction.
        J Exp Med. 2000; 192: 393-404
        • Skulina C.
        • Schmidt S.
        • Dornmair K.
        • Babbe H.
        • Roers A.
        • Rajewsky K.
        • et al.
        Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood.
        Proc Natl Acad Sci USA. 2004; 101: 2428-2433
        • Friese M.A.
        • Fugger L.
        Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?.
        Brain. 2005; 128: 1747-1763
        • Bar-Or A.
        • Calabresi P.A.
        • Arnols D.
        • Markowitz C.
        • Shafer S.
        • Kasper L.H.
        • et al.
        Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open label, phase I trial.
        Ann Neurol. 2008; 63: 395-400
        • Frischer J.M.
        • Bramow S.
        • Dal Bianco A.
        • Lucchinetti C.
        • Rauschka H.
        • Schmidbauer M.
        • et al.
        The relation between inflammation and neurodegeneration in multiple sclerosis.
        Brain. 2009; 132: 1175-1189
        • Anderton S.M.
        • Fillatreau S.
        Activated B cells in autoimmune disease: the case for a regulatory role.
        Nat Clin Pract Rheumatol. 2008; 4: 657-666
        • Ascherio A.
        • Munger K.L.
        Epstein Barr virus infection and multiple sclerosis.
        J Neuroimmune Pharmacol. 2010; (epub ahead of press)
        • Trapp B.D.
        • Nave K.A.
        Multiple sclerosis: an immune or neurodegenerative disorder?.
        Annu Rev Neurosci. 2008; 31: 247-269
        • Hochmeister S.
        • Grundtner R.
        • Bauer J.
        • Engelhardt B.
        • Lyck R.
        • Gordon G.
        • et al.
        Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.
        J Neuropathol Exp Neurol. 2006; 65: 855-865
        • Serafini B.
        • Rosicarelli B.
        • Magliozzi R.
        • Stigliano E.
        • Aloisi F.
        Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.
        Brain Pathol. 2004; 14: 164-174
        • Jabbour E.
        • Thomas D.
        • Cortes J.
        • Kantarjian H.M.
        • O'Brien S.
        Central nervous system prophylaxis in adults with acute lymphobrastic leukemia.
        Cancer. 2010; 116: 2290-2300
        • Algazi A.P.
        • Kadoch C.
        • Rubenstein J.L.
        Biology and treatment of primary central nervous system lymphoma.
        Neurotherapeutics. 2009; 6: 587-597
        • Villela L.
        • Garcia M.
        • Caballero R.
        • Borbolla-Escoboza J.R.
        • Bolanos-Meade J.
        Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma.
        Anticancer Drugs. 2008; 19: 917-920
        • Sifrin V.
        • Vogt J.
        • Radbruch H.
        • Nitsch R.
        • Zipp F.
        Multiple sclerosis – candidate mechanisms underlying CNS atrophy.
        Trends Neurosci. 2010; 33: 202-210
        • Trapp B.
        • Stys P.
        Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis.
        Lancet Neurol. 2009; 8: 280-291
        • Mahad D.
        • Ziabreva I.
        • Lassmann H.
        • Turnbull D.
        Mitochondrial defects in acute multiple sclerosis lesions.
        Brain. 2008; 131: 1722-1735
        • Veto S.
        • Acs P.
        • Bauer J.
        • Lassmann H.
        • Berente Z.
        • Setalo G.
        • et al.
        Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.
        Brain. 2010; 133: 822-834
        • Stys P.K.
        General mechanisms of axonal damage and its prevention.
        J Neurol Sci. 2005; 133: 3-13
        • Mahad D.
        • Ziabreva I.
        • Campbell G.
        • Lax N.
        • Hanson P.S.
        • Lassmann H.
        • et al.
        Mitochondrial changes within axons in multiple sclerosis.
        Brain. 2009; 132: 1161-1174
        • Dutta R.
        • McDonough J.
        • Yin X.
        • Peterson J.
        • Chang A.
        • Torres T.
        • et al.
        Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
        Ann Neurol. 2006; 59: 478-489
        • Goodman A.D.
        • Brown T.R.
        • Krupp L.B.
        • Schapiro R.T.
        • Schwid S.R.
        • Cohen R.
        • et al.
        • on behalf of the Fampridine MS-F203 investigation
        Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
        Lancet. 2009; 373: 732-738
        • Lisak R.P.
        • Benjamins J.A.
        • Bealmear B.
        • Nedelkoska L.
        • Studzinski D.
        • Redland E.
        • et al.
        Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation.
        J Neuroinflammation. 2009; 4: 30
        • Smith K.J.
        • Kapoor R.
        • Felts P.A.
        Demyelination: the role of oxygen and nitrogen species.
        Brain Pathol. 1999; 9: 69-92
        • Lu F.
        • Selak M.
        • O'Connor J.
        • Croul S.
        • Lorenzana C.
        • Butunoi C.
        • et al.
        Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis.
        J Neurol Sci. 2000; 177: 95-103
        • Gray E.
        • Thomas T.L.
        • Betmouni S.
        • Scolding N.
        • Love S.
        Elevated myeloperoxidase activity in white matter in multiple sclerosis.
        Neurosci Lett. 2008; 442: 195-198
        • Gray E.
        • Thomas T.L.
        • Betmouni S.
        • Scolding N.
        • Love S.
        Elevated activity of microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis.
        Brain Pathol. 2008; 18: 86-95
        • Hammond K.E.
        • Metcalf M.
        • Carvajal L.
        • Okuda D.T.
        • Srinivasan R.
        • Vigneron D.
        • et al.
        Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron.
        Ann Neurol. 2008; 64: 707-713